This Article Full Text Full Text (PDF) All Versions of this Article: 90/1/168    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bitnun, A. Articles by King, S. M. Search for Related Content PubMed PubMed Citation Articles by Bitnun, A. Articles by King, S. M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Diabetes and Insulin

Insulin Sensitivity and ß-Cell Function in Protease Inhibitor-Treated and -Naive Human Immunodeficiency Virus-Infected Children

Divisions of Infectious Diseases (A.B., S.R., S.M.K.) and Endocrinology and Diabetes (E.S., C.J.), Department of Pediatrics, and Departments of Radiology (P.B.) and Pediatrics and Health Policy, Management, and Evaluation (P.T.D., T.T.), The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada M5G 1X8; and Department of Pediatrics (J.F.), University of British Columbia, Vancouver, Canada V6H 3N1

Address all correspondence and requests for reprints to: Ari Bitnun, M.D., M.Sc., F.R.C.P.C., Division of Infectious Diseases, Department of Pediatrics, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8. E-mail: ari.bitnun{at}sickkids.ca.

Previous pediatric studies have failed to demonstrate a clear association between protease inhibitor (PI) therapy and abnormal glucose homeostasis in HIV-infected children. To define more precisely the impact of PI therapy on glucose homeostasis in this population, we performed the insulin-modified frequent-sampling iv glucose tolerance test on 33 PI-treated and 15 PI-naive HIV-infected children. Other investigations included fasting serum lipids; glucose, insulin, and C-peptide; single-slice abdominal computed tomography; and, in a subset of PI-treated children, an oral glucose tolerance test.

There were no differences between the two groups with respect to fasting serum insulin or C-peptide, homeostatic model assessment insulin resistance, or quantitative insulin sensitivity check index. The mean insulin sensitivity index of PI-treated and PI-naive children was 6.93 ± 6.37 and 10.58 ± 12.93 x 10^–4min^–1 [µU/ml]^–1, respectively (P = 0.17). The mean disposition index for the two groups was 1840 ± 1575 and 3708 ± 3005 x 10^–4min^–1 (P = 0.013), respectively. After adjusting for potential confounding variables using multiple regression analysis, the insulin sensitivity index and disposition index of PI-treated children were significantly lower than that of PI-naive children (P = 0.01 for both). In PI-treated but not PI-naive children, insulin sensitivity correlated inversely with visceral adipose tissue area (r = –0.43, P = 0.01) and visceral to sc adipose tissue ratio (r = –0.49, P = 0.004). Mildly impaired glucose tolerance was noted in four of 21 PI-treated subjects tested.

Our results demonstrate not only that PI therapy reduces insulin sensitivity in HIV-infected children but also that it impairs the ß-cell response to this reduction in insulin sensitivity and, in a subset of children, leads to the development of impaired glucose tolerance. The presence of insulin resistance, dyslipidemia, and the significant correlation of reduced insulin sensitivity with increased visceral adipose tissue content suggest that PI-containing highly active antiretroviral therapy is associated with the emergence of early features of a metabolic syndrome-like phenotype.

This article has been cited by other articles:

				J. H. Stein, C. M. Hadigan, T. T. Brown, E. Chadwick, J. Feinberg, N. Friis-Moller, A. Ganesan, M. J. Glesby, D. Hardy, R. C. Kaplan, et al. Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients Circulation, July 8, 2008; 118(2): e54 - e60. [Full Text] [PDF]

				R. Manfredi and L. Calza HIV infection and the pancreas: risk factors and potential management guidelines Int J STD AIDS, February 1, 2008; 19(2): 99 - 105. [Abstract] [Full Text] [PDF]

				R. Rosso, A. Parodi, G. d'Annunzio, F. Ginocchio, L. Nicolini, C. Torrisi, M. P. Sormani, R. Lorini, C. Viscoli, and M. Vignolo Evaluation of insulin resistance in a cohort of HIV-infected youth Eur. J. Endocrinol., November 1, 2007; 157(5): 655 - 659. [Abstract] [Full Text] [PDF]

				M. Charakida, A. E. Donald, H. Green, C. Storry, M. Clapson, M. Caslake, D. T. Dunn, J. P. Halcox, D. M. Gibb, N. J. Klein, et al. Early Structural and Functional Changes of the Vasculature in HIV-Infected Children: Impact of Disease and Antiretroviral Therapy Circulation, July 5, 2005; 112(1): 103 - 109. [Abstract] [Full Text] [PDF]